Reviewing GlucoTrack (NASDAQ:GCTK) & Accuray (NASDAQ:ARAY)

Accuray (NASDAQ:ARAY) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.

Risk and Volatility

Accuray has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, GlucoTrack has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500.

Profitability

This table compares Accuray and GlucoTrack’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Accuray	-3.72%	-36.93%	-3.52%
GlucoTrack	N/A	-826.43%	-707.26%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Accuray and GlucoTrack, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	0	0	2	0	3.00
GlucoTrack	0	0	0	0	0.00

Accuray currently has a consensus price target of $9.00, suggesting a potential upside of 334.78%. Given Accuray’s stronger consensus rating and higher possible upside, research analysts plainly believe Accuray is more favorable than GlucoTrack.

Institutional & Insider Ownership

64.1% of Accuray shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 4.2% of Accuray shares are held by company insiders. Comparatively, 46.5% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Accuray and GlucoTrack”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$444.20 million	0.47	-$15.55 million	($0.17)	-12.18
GlucoTrack	N/A	N/A	-$7.10 million	($2.83)	-0.10

GlucoTrack has lower revenue, but higher earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Summary

Accuray beats GlucoTrack on 9 of the 13 factors compared between the two stocks.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

About GlucoTrack

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.